Drug–Drug Interactions in the Treatment of Cancer-Associated Venous Thromboembolism with Direct Oral Anticoagulants

 

 Buy Article Permissions and Reprints

Abstract

Venous thromboembolism (VTE) is a frequent complication of cancer, and management of cancer-associated thrombosis (CAT) is challenging due to increased risks of bleeding and recurrent VTE. Recent trials have shown an acceptable efficacy and safety of direct oral anticoagulants (DOACs) in the treatment of CAT compared to low-molecular weight heparin. Although DOACs provide an effective and convenient treatment option in CAT, the need to assess the risk of drug–drug interactions (DDI) with antineoplastic therapies poses a barrier to their use in clinical practice. With the aim of supporting the assessment of CAT patients for treatment with DOAC, this review provides a comprehensive overview of the compatibility of antineoplastic therapies with the individual DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban). Using several data sources, we characterized 100 widely used antineoplastic agents with regard to their effect on p-glycoprotein and cytochrome P450, both important in the transport and elimination of DOACs. This enabled us to evaluate 400 “DOAC-antineoplastic agent”-pairs regarding their likelihood to interact (unlikely, potential, or likely), ultimately leading to clinical recommendations on the appropriateness of concomitant use for each pair. A potential or likely DDI was identified for 12% of the evaluated pairs. For nearly all antineoplastic agents, at least one DOAC was considered compatible.

Publication History

Article published online:
02 February 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Jensvoll H, Severinsen MT, Hammerstrøm J. et al. Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clin Epidemiol 2015; 7: 401-410
  CrossrefPubMedGoogle Scholar
• 2 Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009; 27 (29) 4902-4911
  CrossrefPubMedGoogle Scholar
• 3 Kourlaba G, Relakis J, Mylonas C. et al. The humanistic and economic burden of venous thromboembolism in cancer patients: a systematic review. Blood Coagul Fibrinolysis 2015; 26 (01) 13-31
  CrossrefPubMedGoogle Scholar
• 4 Prandoni P, Lensing AWA, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
  CrossrefPubMedGoogle Scholar
• 5 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
  CrossrefPubMedGoogle Scholar
• 6 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
  CrossrefPubMedGoogle Scholar
• 7 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
  CrossrefPubMedGoogle Scholar
• 8 Khorana AA, Noble S, Lee AYY. et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (09) 1891-1894
  CrossrefPubMedGoogle Scholar
• 9 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20 (10) e566-e581
  CrossrefPubMedGoogle Scholar
• 10 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38 (05) 496-520
  CrossrefPubMedGoogle Scholar
• 11 Sabatino J, De Rosa S, Polimeni A, Sorrentino S, Indolfi C. Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis. JACC CardioOncol 2020; 2 (03) 428-440
  CrossrefPubMedGoogle Scholar
• 12 European Medicines Agency. Guideline on the investigation of drug interactions. Published online 2012. Accessed February 01, 2021, at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf
  PubMedGoogle Scholar
• 13 Steffel J, Collins R, Antz M. et al; 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23 (10) 1612-1676
  CrossrefPubMedGoogle Scholar
• 14 Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res 2016; 111: 592-599
  CrossrefPubMedGoogle Scholar
• 15 European Medicines Agency. Eliquis: Summary of Product Characteristics (updated September 2022). Published online 2022. Accessed 15 September 2022 at: https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis#product-information-section
  PubMedGoogle Scholar
• 16 European Medicines Agency. Xarelto: Summary of Product Characteristics (updated December 2021). Published online 2021. Accessed 15 September 2022 at: https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto
  PubMedGoogle Scholar
• 17 European Medicines Agency. Pradaxa: Summary of Product Characteristics (updated July 2022). Published online 2022. Accessed 15 September 2022 at: https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa#product-information-section
  PubMedGoogle Scholar
• 18 European Medicines Agency. Lixiana: Summary of Product Characteristics (updated April 2021). Published online 2021. Accessed 15 September 2022 at: https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana#product-information-section
  PubMedGoogle Scholar
• 19 Hodin S, Basset T, Jacqueroux E. et al. In vitro comparison of the role of P-glycoprotein and breast cancer resistance protein on direct oral anticoagulants disposition. Eur J Drug Metab Pharmacokinet 2018; 43 (02) 183-191
  CrossrefPubMedGoogle Scholar
• 20 Foerster KI, Hermann S, Mikus G, Haefeli WE. Drug-drug interactions with direct oral anticoagulants. Clin Pharmacokinet 2020; 59 (08) 967-980
  CrossrefPubMedGoogle Scholar
• 21 European Medicines Agency. European Medicines Agency. Accessed February 2, 2021, at: https://www.ema.europa.eu/en
  PubMedGoogle Scholar
• 22 U.S. Food and Drug Administration. . FDA. Published August 23, 2021. Accessed August 24, 2021, at: https://www.fda.gov/home
  PubMed
• 23 Danish Medicines Agency. . Produktresuméer. Accessed August 24, 2021, at: http://www.produktresume.dk/AppBuilder/search
  PubMed
• 24 Micromedex IBM. . (R). Accessed February 2, 2021, at: https://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.DoIntegratedSearch/ssl/true?navitem=headerLogout#
  PubMed
• 25 Lund M, Petersen TS, Dalhoff KP. Clinical implications of p-glycoprotein modulation in drug-drug interactions. Drugs 2017; 77 (08) 859-883
  CrossrefPubMedGoogle Scholar
• 26 Danish Medicines Agency. . Interaktionsdatabasen.dk. Accessed February 2, 2021, at: http://www.interaktionsdatabasen.dk/
  PubMed
• 27 U.S. Food and Drug Adminstration. Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. Guidance for Industry. Published online 2020. Accessed 15 September 2022 at: https://www.fda.gov/media/134581/download
  PubMedGoogle Scholar
• 28 Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P. Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin Pharmacokinet 2017; 56 (03) 235-250
  CrossrefPubMedGoogle Scholar
• 29 Verso M, Munoz A, Bauersachs R. et al. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J Cancer 2021; 148: 371-381
  CrossrefPubMedGoogle Scholar
• 30 Wang CL, Wu VC, Tu HT. et al. Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation. J Thromb Thrombolysis 2022; 53 (03) 633-645
  CrossrefPubMedGoogle Scholar
• 31 Bikdeli B, Jiménez D. Safety of apixaban for cancer-associated thrombosis. Thromb Haemost 2021; 121 (05) 547-551
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Picker N, Lee AY, Cohen AT. et al. Anticoagulation treatment in cancer-associated venous thromboembolism: assessment of patient preferences using a discrete choice experiment (COSIMO study). Thromb Haemost 2021; 121 (02) 206-215
  Article in Thieme ConnectPubMedGoogle Scholar
• 33 Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G. Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica 2015; 100 (11) 1486-1492
  CrossrefPubMedGoogle Scholar

• Supplementary Material